» Articles » PMID: 26968102

Multiple Approaches to Assess Fourteen Non-invasive Serum Indexes for the Diagnosis of Liver Fibrosis in Chronic Hepatitis C Patients

Overview
Journal Clin Biochem
Specialty Biochemistry
Date 2016 Mar 13
PMID 26968102
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this study was to compare fourteen non-invasive indexes/scores: AAR, APRI, Fibroindex, MODEL3, Forns index, FIB4, GUCI, FI, FCI, Pohl score, AP index, CDS, HGM-1 and HGM-2, in order to diagnose the hepatic fibrosis stage in a survey of patients with chronic hepatitis C.

Methods: 84 patients with chronic hepatitis C were studied. Liver fibrosis was staged according to the Scheuer scoring system. The diagnostic accuracy of these indexes/scores was evaluated by AUROC, contingency tables and logistic regression analysis.

Results: The best AUROCs (>0.9) to discriminate cirrhosis (F=4), were observed for CDS, FI, AAR, MODEL3, FIB4, HGM-2 and FCI. To discriminate at least advance fibrosis (F≥3), the best AUROCs (>0.89) were for CDS, FI, FIB4, HGM2-2, MODEL3 and FCI. To discriminate at least significant fibrosis (F≥2), the best AUROCs (>0.8) were for FIB4, GUCI, APRI, FI, Forns index, HGM-2 and FCI. Contingency tables and logistic regression analysis supported the results obtained by AUROC.

Conclusions: This study compares the diagnostic performance of fourteen indexes for the diagnosis of liver fibrosis stage in the same group of CHC patients. These results allow the selection of the best indexes for further studies in larger populations, in order to build diagnostic algorithms as an alternative to liver biopsy for fibrosis staging in patients with chronic HCV infection. These algorithms would allow to take therapeutical decisions and the continuous follow-up of hepatic fibrosis in these patients.

Citing Articles

Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.

Huttman M, Parigi T, Zoncape M, Liguori A, Kalafateli M, Noel-Storr A Cochrane Database Syst Rev. 2024; 8:CD011929.

PMID: 39136280 PMC: 11320661. DOI: 10.1002/14651858.CD011929.pub2.


Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable?.

Ma S, Zhou L, Lin S, Li M, Luo J, Chen L Diagnostics (Basel). 2024; 14(5).

PMID: 38472929 PMC: 10930419. DOI: 10.3390/diagnostics14050456.


Investigation of liver fibrosis with serum biochemical parameters before treatment with direct-acting antivirals, at the end of treatment, and in the first and third year after treatment in patients with chronic hepatitis C.

Bozkurt M, Zerdali E, Pehlivanoglu F Clin Exp Hepatol. 2023; 9(1):21-27.

PMID: 37064837 PMC: 10090997. DOI: 10.5114/ceh.2023.125917.


A Nomogram for Predicting Portal Hypertensive Gastropathy in Patients With Liver Cirrhosis: A Retrospective Analysis.

Wang W, Mu Z, Zhu G, Wang T, Lai S, Guo Y Front Med (Lausanne). 2022; 9:834159.

PMID: 35252265 PMC: 8894675. DOI: 10.3389/fmed.2022.834159.


A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.

Duerr M, Schrezenmeier E, Lehner L, Bergfeld L, Glander P, Marticorena Garcia S BMC Nephrol. 2019; 20(1):36.

PMID: 30717681 PMC: 6360788. DOI: 10.1186/s12882-019-1218-0.